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Abstract
Objectives. While many axSpA patients, eligible to receive anti-TNFa therapy, derive benefit when prescribed
them, some patients do not. The current study aims to identify modifiable targets to improve outcome as well as
non-modifiable targets that identify groups less likely to derive benefit.
Methods. The BSRBR-AS is a prospective cohort study of axSpA patients who, at recruitment, were naı¨ve to bio-
logic therapy. Those in the ‘biologic’ sub-cohort commenced their first anti-TNFa therapy at recruitment or during
follow-up. Prior to commencement, information was collected on socio-economic, clinical and patient-reported fac-
tors. Outcome was assessed according to ASAS20, ASAS40, ASDAS reduction and achieving a moderate/inactive
ASDAS disease state.
Results. 335 participants commenced their first anti-TNFa therapy and were followed up at a median of 14 (inter-
quartile range 12–17) weeks. Response varied between 33% and 52% according to criteria used. Adverse socio-
economic factors, fewer years in education predicted lower likelihood of response across outcome measures as
did not working full-time. Co-morbidities and poor mental health were clinical and patient-reported factors, respect-
ively, associated with lack of response. The models, particularly those using ASDAS, were good at predicting those
who did not respond (negative predictive value (NPV) 77%).
Conclusion. Some factors predicting non-response (such as mental health) are modifiable but many (such as so-
cial/economic factors) are not modifiable in clinic. They do, however, identify patients who are unlikely to benefit
from biologic therapy alone. Priority should focus on how these patients receive the benefits that many derive from
such therapies.
Key words: axial spondyloarthritis, ankylosing spondylitis, response, treatment, anti-TNF-alpha, biologic
therapy
Introduction
The introduction of anti-TNF-a therapies has transformed
the outlook for patients with inflammatory arthritis, includ-
ing axial spondyloarthritis (axSpA). They have resulted in
clinically important benefits in terms of improving function
and quality of life [1, 2] and have improved wider out-
comes such as fatigue (in RA) and work productivity (in
AxSpA) [3, 4]. Of course, the studies report average
affects and within approaches to management that show
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overall benefit, there will be people who do not respond
to therapy or show less improvement. Indeed, in a real-
world setting, of patients with axSpA commenced on a
first anti-TNFa agent, around one in four will no longer be
on the agent 12 months later [5].
Patients who are obese have been reported as less
likely to respond to anti-TNFa therapies in axSpA and RA
[6] and RA patients with symptoms of depression are
less likely to achieve a good response to biologic therapy
[7]. It has been hypothesized that patients with axSpA
who have co-morbid fibromyalgia may have distorted dis-
ease indices, receive anti-TNFa therapy inappropriately
and if they do, that they derive less benefit. However we
have shown, using data from the British Society for
Rheumatology Biologics Register in Ankylosing
Spondylitis (BSRBR-AS) that there is only a very small ef-
fect of meeting criteria for fibromyalgia per se on disease
indices such as the Bath Index of Disease Activity
(BASDAI) and the magnitude of improvement is no differ-
ent to those who do not meet criteria for fibromyalgia [8].
The aim of the current study was to identify factors
(including socio-economic, clinical and patient reported)
that characterized axSpA patients who were less likely
to respond to their first anti-TNFa therapy. Identifying
such factors is, in general, important in terms of provid-
ing optimal management and can provide a focus of re-
search to understand the mechanisms that lead to lack
of improvement in people with certain characteristics.
Methods
The BSRBR-AS is a prospective cohort study of axSpA
patients who, at recruitment, were naı¨ve to biologic ther-
apy. Recruitment took place in 83 secondary care
centres across the Great Britain between December 2012
and December 2017, for those patients aged at least
16 years meeting the Assessment of SpondyloArthritis
international Society (ASAS) imaging criteria for axSpA [9]
or the modified New York (mNY) definition of ankylosing
spondylitis (AS) [10]. From November 2014, those meet-
ing the ASAS clinical criteria were also eligible. Details of
the study protocol have previously been published [11].
There are two sub-cohorts: those commencing their first
anti-TNFa therapy at the time of recruitment (primarily the
agents adalimumab, etanercept and certolizumab pegol)
thereafter named the ‘biologic cohort’ and those remain-
ing on other therapies (‘non-biologic cohort’). The biologic
cohort was followed-up at 3 months and 6 months, and
both cohorts were seen at 12 months and yearly there-
after to a maximum of 5 years. In addition to clinical data,
patient reported questionnaires were completed at each
follow-up. If a patient in the non-biologic cohort com-
menced anti-TNFa therapy, they switched sub-cohort
and began a new follow-up schedule.
The primary outcome of interest for the current ana-
lysis is response to first anti-TNFa therapy at initial
follow-up, defined as the first contact with the study in
the period 10 weeks to 9 months after commencement.
This period was chosen in order to measure outcome
within the first two follow-up periods of the study (but
allowing for early or late clinic visits). We looked at a
variety of outcome measures to determine to what ex-
tent there was consistency in predictors or alternatively
whether predictors were importantly related to the pre-
cise outcome measure used. Response was therefore
defined in the following ways:
. meeting ASAS20 and ASAS40 improvement criteria
[12, 13];
. exhibiting a clinically important improvement in the
Ankylosing Spondylitis Disease Activity Score (ASDAS)
– a reduction of 1.1; and
. moving from a high or very high ASDAS disease activity
state (score 2.1) to a moderate or inactive disease
state (score <2.1) [14, 15].
Measures collected at recruitment (baseline), used in
the current analysis as potential predictors of response
include those listed below.
Clinical data
The following were recorded: the classification criteria
fulfilled (ASAS imaging, ASAS clinical or mNY), presence
of extra-spinal manifestations (history of uveitis, psoria-
sis, IBD, peripheral joint involvement and clinically
assessed heel enthesitis and dactylitis), count of comor-
bidities (specifically, the presence of angina, congestive
heart failure, stroke, hypertension, diabetes, asthma,
bronchitis, peptic ulcer, liver disease, renal disease, tu-
berculosis, demyelination, depression and malignancy).
The following were measured: BMI, inflammatory
markers (CRP or ESR), HLA-B27 status, physician-
assessed swollen/tender joint count and the BASMI
scored 0 (least) to 10 (most severe) [16].
Patient reported socio-economic, health and lifestyle
measures
Using study questionnaires, information was collected on:
socio-economic factors (level of education, employment
status at recruitment), lifestyle factors (tobacco smoking
and alcohol intake) and quality of life, assessed by the
AS Quality of Life index (ASQoL) scored from 0 (best) to
18 (worst) [17], and the Short Form 12 Physical and
Mental component scores, scored from 0 (worst) to 100
(best) [18]. Mental health was assessed by the Hospital
Anxiety and Depression Scale (HADS) scored from 0
(best) to 21 (worst) [19] and overall work and other activ-
ity impairment using the Work Productivity and Activity
Impairment Specific Health Problem (WPAI: SHP), both
scored from 0–100% [20, 21]. Spinal pain was assessed
using a 10 cm visual analogue scale, fatigue through the
Chalder Fatigue Scale (CFS) (0–11) [22], and sleep dis-
turbance by the Jenkins Sleep Evaluation Questionnaire
(0–20) [23], with higher scores on each indicating worse
state. Lastly, the Bath Ankylosing Spondylitis indices
were included to provide measures of disease activity
(BASDAI), function (BASFI) and global health (BAS-G) [all
scored from 0 (best) to 10 (worst)] [24–26]. Information
provided by participants on their address was used to
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derive a measure of local area deprivation according to
quintiles (based on the distribution of their country of resi-
dence within the UK) from 1 (least deprived) to 5 (most
deprived) [27, 28]. For those recruited after September
2015, information was collected on the 2011 research cri-
teria for fibromyalgia [29].
The BSRBR-AS received ethical approval from the UK
National Research Ethics Service (NRES) Committee
North East – County Durham and Tees Valley (REC ref
11/NE/0374).
Statistical analysis
For the purpose of the current analysis, participants who
joined the biologic sub-cohort were eligible. The relation-
ship between the clinical and patient reported (including
socio-economic) baseline factors and each of the follow-
up response criteria were assessed, initially by logistic re-
gression models, with results given as odds ratios (OR)
and 95% CI. Continuous variables or counts were
retained as such during all analyses and assessed for
their association with outcome per unit increase. For di-
chotomous factors, such as a history of uveitis, the pres-
ence of each was assessed for association with outcome
compared with the absence (yes vs no). Smoking status
was categorized into never, ex and current smoking.
Current smokers were further dichotomized as </ the
median level of smoking (10 products/day). Alcohol con-
sumption was categorized as never, ex and current, with
current drinkers dichotomized />14 units of alcohol per
week (i.e. the maximum consumption recommended by
the National Health Service [30]). For all multi-level cat-
egorical factors, including smoking and alcohol status,
reference categories were selected.
Those factors reaching a significance threshold of
P 0.2 were offered to individual forward stepwise logistic
regression models in order to determine the group of fac-
tors that best predict response (according to each of the
response criteria examined). Factors entered the stepwise
model at P  0.15 and exited at P  0.10. The fit of the
final models was assessed through the calculation of the
area under the receiver operator characteristic (ROC)
curve (95% CI), sensitivity and specificity in addition to the
positive and negative predictive values (PPV/NPV).
All analysis was conducted using STATA (StataCorp
LP version 15.0) and uses the August 2017 version of
the dataset.
Results
The timing of patient follow-up from commencing first
anti-TNF therapy to measuring response in the current
analysis is a median of 14 weeks with an inter-quartile
range (IQR) of 12–17 weeks. At this time, 95% were still
taking their first anti-TNF.
Baseline characteristics of study population
A total of 335 participants were eligible for the current
analysis: 69% male, with median age 47 years (IQR 36–56)
and median BMI of 27.2kgm2 (IQR 24.1, 31.1) (Tables 1
and 2). The only important difference between those who
were included in this analysis (i.e. had follow-up clinic visit
and provided patient reported outcome measures) and
those who were not, was deprivation. Of those included,
49.8% were from the two least deprived quintiles in com-
parison to 34.4% of those not included. The majority of
participants (63.9%) were, at time of commencing therapy
working full or part-time while 19.2% were unemployed or
had retired due to ill-health. Approximately two-thirds of
participants met mNY criteria for AS (61.2%), one-third
met ASAS imaging criteria but not mNY criteria for AS
(34.9%), while only a small proportion met only ASAS clin-
ical criteria (3.9%), mainly as a result of these only be-
come eligible criteria part-way through the recruitment
period; 76.5% of those tested were HLA B-27 positive. In
terms of disease activity, 95.7% were classified as having
high or very high disease activity with an ASDAS score
2.1, while 90.8% had a BASDAI score of at least 4.
Overall, the patient population had high median levels of
TABLE 1 Baseline socio-economic and lifestyle character-
istics of those commencing biologic therapy
n Median
(IQR)
Age years 335 46.6 (36.4,
56.1)
n %
Gender Male 230 (68.7)
Education Secondary school 117 (35.4)
Apprentice 36 (10.9)
College 86 (26.0)
University degree 67 (20.2)
Further degree 25 (7.5)
Employment Full-time 165 (49.6)
Part-time 48 (14.4)
Unpaid/seeking 15 (4.5)
Retired 37 (11.1)
Retired/unemployed
due to ill-health
64 (19.2)
Student 4 (1.2)
Deprivationa 1 (least deprived) 80 (23.9)
2 87 (26.0)
3 66 (19.7)
4 55 (16.4)
5 (most deprived) 47 (14.0)
Smoking Never 142 (43.3)
Ex-smoker 111 (33.8)
Current – light 31 (9.5)
Current – heavy 44 (13.4)
Alcohol
drinking
Never 26 (7.8)
Ex drinker 57 (17.1)
Current – 14
units/week
228 (68.5)
Current – >14
units/week
22 (6.6)
IQR, inter-quartile range. aQuintiles of general population
distribution.
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fatigue (CFS score 6.0), sleep disturbance (Jenkins score
14.0), anxiety (HADS anxiety score 9.0) and depression
(HADS depression score 8.0) (Table 2).
Predictors of meeting ASAS20 response
ASAS20 response criteria was achieved by 52%
(n¼175) of participants. Univariable logistic regression
identified several baseline factors associated with lack
of response which were eligible as candidates for the
stepwise model (P  0.2) (Tables 3–5). Demographic
factors included: older age, education up to secondary
school and not being in full-time employment. Clinical
factors included: higher BMI, peripheral joint involve-
ment, no history of uveitis or dactylitis and less
favourable BASMI. Patient reported factors included:
better disease activity (ASDAS), poorer mental health
(Short Form 12 Mental Component Score (SF-12 MCS),
HADS), poorer physical function and overall physical
health (BASFI, Short Form 12 Physical Component
Score (SF12 PCS)), worse quality of life (ASQoL) and
higher levels of fatigue and activity impairment. On
stepwise logistic regression modelling, three factors in-
dependently predicted lack of ASAS20 response
(Table 6): not being in full-time employment, higher BMI
[OR of response 0.96 per unit increase 95% CI (0.91,
1.003)] and higher initial levels of anxiety [0.94 per unit
score increase (0.88, 0.998)]. The model demonstrated
a good level of fit (ROC 0.68) with PPV 63%, and NPV
65%.
TABLE 2 Baseline clinical and patient-reported health characteristics of those commencing biologic therapy
n %
Disease criteria Modified New York 205 (61.2)
ASAS imaging 117 (34.9)
ASAS clinical 13 (3.9)
First biologic Adalimumab 223 (66.6)
Etanercept 78 (23.3)
Certolizumab pegol 33 (9.8)
Golimumab 1 (0.3)
Extra-spinal manifestations Heel enthesitis present 38 (11.4)
Uveitis present 78 (23.4)
Dactylitis present 16 (4.8)
Psoriasis present 32 (9.6)
IBD present 38 (11.4)
Peripheral joint disease present 74 (22.2)
n Median (IQR)
BMI kg/m2 267 27.2 (24.1, 31.1)
CRP (mg/dl) mg/dl 287 0.70 (0.2, 2.2)
Tender joint count range: 0–44 323 0 (0, 0)
Swollen joint count range: 0–40 318 0 (0, 0)
Spinal mobility BASMI: 0 (best) – 10 (worst) 259 4.4 (2.8, 5.6)
Comorbidity count range: 0 – 14 332 0 (0, 1)
SF-12 – MCS Scored: 0 (worst) – 100 (best) 326 42.8 (35.5, 53.1)
SF-12 – PCS Scored: 0 (worst) – 100 (best) 326 32.3 (24.1, 39.8)
Disease activity BASDAI: 0 (best) – 10 (worst) 335 6.7 (5.4, 7.8)
ASDAS: (higher score worse) 300 3.7 (3.2, 4.5)
Physical function BASFI: 0 (best) – 10 (worst) 335 6.7 (5.0, 8.1)
Global health BASG: 0 (best) – 10 (worst) 334 7.5 (6.0, 8.5)
Spinal mobility BASMI: 0 (best) – 10 (worst) 259 4.4 (2.8, 5.6)
Quality of life ASQoL: 0 (best) – 18 (worst) 332 12 (9, 15)
Fatigue CFS: 0 (best) – 11 (worst) 335 6 (3, 9)
Sleep disturbance Jenkins: 0 (best) – 20 (worst) 332 14 (8, 18)
Overall work impairment % 183 40 (30, 70)
Activity impairment % 329 70 (50, 80)
Anxiety HADS: 0 (best) – 21 (worst) 333 9 (6, 12)
Depression HADS: 0 (best) – 21 (worst) 333 8 (4, 10)
Spinal pain VAS: 0 (best) – 10 (worst) 335 7 (5, 8)
ASAS: assessment in ankylosing spondylitis; SF-12 MCS: short form 12 mental component score; SF-12 PCS: short form
12 physical component score; BASDAI: Bath ankylosing spondylitis disease activity index; BASFI: Bath ankylosing spondyl-
itis functional index; ASDAS: ankylosing spondylitis disease activity score; BASG: Bath ankylosing spondylitis global score;
BASMI: Bath ankylosing spondylitis metrology index; ASQoL: ankylosing spondylitis quality of life index; CFS: Chalder fa-
tigue scale; HADS: hospital anxiety and depression scale; VAS: visual analogue scale; IQR, inter-quartile range.
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TABLE 3 Associations of socio-economic baseline factors with each response measure at follow-up (univariable logistic
regression analyses)
ASAS 20
response
ASAS 40
response
ASDAS 1.1
reduction
ASDAS
score <2.1
Baseline variables OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age Per year 0.99 (0.97, 1.004) 0.99 (0.97, 1.01) 0.99 (0.97, 1.01) 0.99 (0.97, 1.01)
Gender Female vs male 1.01 (0.64, 1.60) 0.69 (0.42, 1.14) 0.65 (0.38, 1.11) 0.66 (0.37, 1.18)
Education Secondary school Ref Ref Ref Ref
Apprentice 1.90 (0.89, 4.07) 2.02 (0.91, 4.47) 1.65 (0.70, 3.93) 1.97 (0.80, 4.86)
College 1.00 (0.57, 1.75) 1.45 (0.78, 2.71) 0.64 (0.33, 1.02) 1.17 (0.57, 2.42)
University degree 2.31 (1.24, 4.30) 3.09 (1.63, 5.85) 1.20 (0.91, 2.37) 2.64 (1.26, 5.53)
Further degree 1.81 (0.75, 4.36) 1.50 (0.58, 3.84) 0.53 (0.20, 1.45) 3.51 (1.29, 9.54)
Employment Full-time Ref Ref Ref Ref
Part-time 0.48 (0.25, 0.92) 0.36 (0.17, 0.77) 0.39 (0.18, 0.82) 0.23 (0.09, 0.57)
Unpaid/seeking 1.24 (0.40, 3.78) 0.90 (0.31, 2.66) 0.26 (0.07, 1.003) 0.21 (0.04, 1.04)
Retired 0.73 (0.35, 1.49) 0.93 (0.45, 1.91) 0.96 (0.43, 2.15) 0.68 (0.30, 1.55)
Retired/
unemployed
due to ill-health
0.26 (0.14, 0.49) 0.19 (0.09, 0.43) 0.32 (0.16, 0.65) 0.04 (0.01, 0.18)
Student 1.85 (0.19, 18.20) 1.36 (0.19, 9.87) 2.33 (0.24, 23.04) 2.90 (0.29, 28.69)
Deprivation 1 (least deprived) Ref Ref Ref Ref
(quintiles) 2 0.96 (0.52, 1.76) 0.71 (0.38, 1.33) 0.90 (0.45, 1.79) 0.59 (0.29, 1.23)
3 0.73 (0.38, 1.41) 0.55 (0.27, 1.09) 0.49 (0.23, 1.03) 0.39 (0.17, 0.85)
4 0.70 (0.35, 1.39) 0.61 (0.29, 1.25) 0.45 (0.21, 0.99) 0.43 (0.19, 0.99)
5 (most deprived) 0.81 (0.39, 1.67) 0.41 (0.18, 0.93) 0.53 (0.22, 1.25) 0.36 (0.14, 0.93)
Italics indicate variable eligible for stepwise model (P <0.2). ASAS: assessment in ankylosing spondylitis; ASDAS: ankylos-
ing spondylitis disease activity score; OR: odds ratio; ref: reference category.
TABLE 4 Associations of clinical baseline factors with each response measure at follow-up (univariable logistic regression
analyses)
ASAS 20 response ASAS 40
response
ASDAS 1.1
reduction
ASDAS
score <2.1
Baseline variables OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Disease criteria mNY Ref Ref Ref Ref
ASAS imaging 1.05 (0.67, 1.66) 1.16 (0.72, 1.88) 1.11 (0.66, 1.86) 0.89 (0.50, 1.56)
ASAS clinical 1.09 (0.35, 3.35) 1.35 (0.42, 4.27) 1.19 (0.33, 4.26) 1.84 (0.51, 6.62)
Heel enthesitis Yes vs no 1.29 (0.65, 2.56) 1.37 (0.69, 2.75) 2.69 (1.17, 6.20) 1.18 (0.51, 2.73)
Uveitis Yes vs no 1.53 (0.91, 2.56) 1.37 (0.81, 2.32) 1.49 (0.83, 2.67) 1.15 (0.62, 2.12)
Dactylitis Yes vs no 2.08 (0.71, 6.12) 1.62 (0.59, 4.46) 2.15 (0.70, 6.61) 1.63 (0.53, 5.01)
Psoriasis Yes vs no 1.20 (0.57, 2.49) 0.91 (0.42, 2.003) 0.69 (0.30, 1.59) 0.80 (0.33, 1.93)
IBD Yes vs no 0.80 (0.41, 1.58) 0.60 (0.27, 1.31) 0.42 (0.18, 0.99) 0.76 (0.32, 1.81)
Peripheral joint
disease
Yes vs no 0.63 (0.37, 1.06) 0.64 (0.36, 1.14) 0.83 (0.46, 1.05) 0.87 (0.46, 1.67)
CRP (mg/dl) Per unit increase 0.99 (0.99, 1.01) 1.002 (0.99, 1.01) 1.004 (0.99, 1.02) 0.99 (0.97, 1.01)
Tender joint count Per unit increase 0.97 (0.92, 1.02) 0.98 (0.93, 1.04) 1.003 (0.95, 1.06) 0.98 (0.92, 1.05)
Swollen joint count Per unit increase 0.96 (0.87, 1.06) 0.94 (0.82, 1.08) 0.97 (0.88, 1.08) 0.93 (0.79, 1.08)
BMI (per kg/m2) Per unit increase 0.95 (0.91, 0.99) 0.95 (0.90, 0.99) 0.97 (0.92, 1.02) 0.94 (0.89, 1.001)
BASMI Per unit increase 0.80 (0.70, 0.92) 0.85 (0.73, 0.99) 0.92 (0.80, 1.07) 0.83 (0.70, 0.99)
Comorbidity count Per unit increase 0.65 (0.50, 0.84) 0.57 (0.42, 0.79) 0.60 (0.44, 0.82) 0.51 (0.35, 0.75)
Italics indicate variable eligible for stepwise model (P <0.2). OR: odds ratio; ref: reference category; ASAS: assessment in
ankylosing spondylitis; ASDAS: ankylosing spondylitis disease activity score; BASMI: Bath ankylosing spondylitis metrology
index.
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Predictors of meeting ASAS40 response
At follow-up, 33% (n¼ 111) of patients met ASAS40 re-
sponse criteria. As with ASAS20, in the final model, not
being in full-time employment was associated with lack
of response. Additional factors included education, in
which the less educated were less likely to respond and
a greater number of comorbidities [OR of response 0.64
per additional comorbidity 95% CI (0.45, 0.92)]. In con-
trast to the ASAS20 model, BMI and anxiety were not
included in the final ASAS40 model (although both were
initially associated with ASAS40 outcome). This model
demonstrated a similar level of fit to the ASAS20 model
(ROC curve 0.71) with PPV and NPV of 58% and 72%
respectively.
Predictors of meeting a clinically important
reduction in ASDAS score
Of 261 participants, 122 (47%) met criteria for a clinically
important reduction in ASDAS, and as with the ASAS20/
40 models, there were a wide variety of (mostly similar)
variables that predicted lack of response. Six were
included as independent predictors in the multivariable
analysis (Table 6). As in the ASAS response models, not
being in full-time employment was included in the multi-
variable model. Additional factors included female gen-
der, lower baseline ASDAS score [4.43 per unit increase
95% CI (2.83, 6.94)], poorer mental health [SF-12 MCS:
1.05 per unit increase 95% CI (1.02, 1.09)], more comor-
bidities [0.57 per additional comorbidity 95% CI (0.37,
0.88)] and the absence of enthesitis [3.85 95% CI (1.33,
11.11)]. The final model demonstrated a high level of fit
(ROC 0.85, with PPV 76%, and NPV 77%).
Predictors of moving to a moderate or inactive
(ASDAS) disease state
There were 249 patients eligible for this analysis (i.e. who
had high/very high disease activity at baseline) and who
provided follow-up data. At follow-up, 87 (35%) were clas-
sified as having moderate or inactive disease. The factors
associated with lack of response on univariable analysis
were wide-ranging and very similar to those which pre-
dicted ASAS response although higher initial ASDAS dis-
ease activity was associated with lower likelihood of
achieving a moderate or inactive disease state. Four fac-
tors were included as independent predictors of lack of
response at follow-up (Table 6). Not being in full-time
TABLE 5 Association of patient-reported health and lifestyle factors at baseline, with response at follow-up (multiple uni-
variable logistic regression)
ASAS 20
response
ASAS 40
response
ASDAS 1.1
reduction
ASDAS
score <2.1
Baseline variables OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Smoking Never Refer Ref Ref Ref
Ex 0.82 (0.50, 1.35) 0.83 (0.49, 1.40) 1.01 (0.57, 1.78) 0.66 (0.36, 1.21)
Current – light 0.64 (0.29, 1.39) 0.42 (0.16, 1.08) 1.87 (0.74, 4.76) 0.30 (0.10, 0.97)
Current – heavy 0.71 (0.36, 1.39) 0.90 (0.44, 1.82) 1.37 (0.63, 2.95) 0.72 (0.32, 1.59)
Alcohol drinking Current – 14 units/week Ref Ref Ref Ref
Never 0.34 (0.14, 0.82) 0.22 (0.06, 0.74) 0.89 (0.35, 2.29) 0.20 (0.04, 0.92)
Ex 0.48 (0.27, 0.87) 0.39 (0.19, 0.80) 0.41 (0.20, 0.84) 0.45 (0.21, 0.96)
Current – >14 units/week 1.64 (0.65, 4.19) 1.38 (0.57, 3.32) 1.27 (0.45, 3.56) 1.30 (0.42, 4.05)
SF-12 – MCS Per unit increase 1.03 (1.01, 1.05) 1.02 (1.003, 1.05) 1.02 (1.001, 1.05) 1.06 (1.04, 1.09)
SF-12 – PCS Per unit increase 1.03 (1.01, 1.05) 1.03 (1.01, 1.06) 1.01 (0.99, 1.04) 1.07 (1.03, 1.10)
BASDAI Per unit increase 0.93 (0.82, 1.05) 0.98 (0.87, 1.11) 1.16 (1.01, 1.33) 0.71 (0.60, 0.85)
ASDAS Per unit increase 1.18 (0.94, 1.48) 1.40 (1.10, 1.80) 2.81 (2.03, 3.88) 0.74 (0.55, 0.99)
BASFI Per unit increase 0.90 (0.81, 0.99) 0.92 (0.83, 1.02) 0.99 (0.90, 1.11) 0.70 (0.61, 0.81)
BASG Per unit increase 0.93 (0.81, 1.05) 0.96 (0.84, 1.10) 0.98 (0.85, 1.13) 0.68 (0.57, 0.81)
ASQoL Per unit increase 0.93 (0.88, 0.98) 0.95 (0.90, 0.99) 0.98 (0.93, 1.03) 0.82 (0.76, 0.88)
Fatigue Per unit increase 0.94 (0.89, 1.002) 0.97 (0.91, 1.04) 0.94 (0.88, 1.01) 0.87 (0.80, 0.93)
Sleep disturbance Per unit increase 1.01 (0.97, 1.05) 1.01 (0.97, 1.05) 0.99 (0.96, 1.04) 0.94 (0.89, 0.98)
Activity impairment Per unit increase 0.99 (0.98, 0.99) 0.99 (0.98, 1.004) 0.99 (0.98, 1.004) 0.98 (0.96, 0.99)
HADS anxiety Per unit increase 0.93 (0.88, 0.97) 0.95 (0.90, 1.01) 0.95 (0.90, 1.01) 0.87 (0.81, 0.93)
HADS depression Per unit increase 0.91 (0.86, 0.96) 0.94 (0.89, 1.001) 0.95 (0.89, 1.004) 0.86 (0.80, 0.93)
Spinal VAS Per unit increase 0.97 (0.88, 1.06) 1.02 (0.92, 1.13) 1.11 (0.99, 1.24) 0.84 (0.74, 0.96)
Note: italics indicate variable for stepwise model (P < 0.2). OR: odds ratio; ref: reference category; ASAS: assessment in
ankylosing spondylitis; SF-12 MCS: short form 12 mental component score; SF-12 PCS: short form 12 physical component
score; BASDAI: Bath ankylosing spondylitis disease activity index; BASFI: Bath ankylosing spondylitis functional index;
ASDAS: ankylosing spondylitis disease activity score; BASG: Bath ankylosing spondylitis global score; Bath ankylosing
spondylitis metrology index; ASQoL: ankylosing spondylitis quality of life index; HADS: hospital anxiety and depression
scale; VAS: visual analogue scale.
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employment and lower education level were associated
with lack of response, as was poorer mental health [SF-12
MCS: 1.05 per unit increase 95% CI (1.01, 1.08)] and
more comorbidities [0.60 per additional comorbidity 95%
CI (0.38, 0.95)]. The final model demonstrated a good level
of fit (ROC 0.81) with PPV 63% and NPV 77%.
Running the multivariable models above and adding
data on the total score from the 2011 fibromyalgia crite-
ria, in the subset of subjects with this data available
(n¼141 in whom at least one response criteria could be
calculated), showed that it did not result in important im-
provement in fit to any of the models (data not shown).
Discussion
Irrespective of the specific axSpA response criteria
used, adverse socio-economic factors and fewer years
of education predicted poorer response to initial anti-
TNFa therapy, as did not working full-time. Clinical fac-
tors (co-morbidities) and patient-reported factors (poor
mental health) were also associated with lack of re-
sponse. With the exception of the model predicting
ASDAS reduction, no axSpA-specific clinical variables
were independently predictive of poor outcome and nei-
ther were lifestyle factors (smoking and alcohol con-
sumption). The performance of the models was good,
and in particular there was high NPV for the ASDAS
models (77%) indicating the ability to predict well those
unlikely to meet response criteria. Studies that have
reported that axSpA-specific factors predict response to
TNFa have generally not collected information on socio-
economic factors and may therefore have been affected
by unmeasured confounding [e.g. 31, 32]
The patients in the register were recruited from more
than eighty centres throughout the Great Britain and as
such represent a ‘real-world’ use of anti-TNFa with
greater heterogeneity of clinical features than are
TABLE 6 Baseline factors associated with response at follow-up (stepwise logistic regression models)
ASAS 20
response
ASAS 40
response
ASDAS 1.1
reduction
ASDAS
score <2.1
(model n5 261) (model n5 326) (model n5 253) (model n5239)
Participants meeting response
criteria (%)
52% 33% 47% 35%
Baseline variables OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Employment Full-time Ref – Ref – Ref – Ref –
Part-time 0.48 (0.23, 1.03) 0.38 (0.17, 0.84) 0.39 (0.15, 1.02) 0.28 (0.11, 0.74)
Unpaid/seeking 1.80 (0.53, 6.13) 1.16 (0.38, 3.53) 0.23 (0.04, 1.26) 0.24 (0.05, 1.28)
Retired 0.67 (0.31, 1.47) 1.52 (0.68, 3.43) 1.08 (0.37, 3.15) 0.90 (0.33, 2.47)
Retired/unemployed
due to ill-health
0.37 (0.18, 0.76) 0.26 (0.11, 0.63) 0.29 (0.11, 0.76) 0.04 (0.01, 0.34)
Student Low N. 0.99 (0.13, 7.73) 2.14 (0.12, 38.22) 2.69 (0.26, 27.50)
BMI Per unit increase 0.96 (0.91, 1.003)
Education Secondary school Ref – Ref –
Apprenticeship 1.99 (0.85, 4.64) 1.43 (0.50, 4.08)
College 1.41 (0.72, 2.75) 1.01 (0.43, 2.36)
University degree 2.82 (1.41, 5.61) 1.72 (0.72, 4.10)
Further degree 1.27 (0.47, 3.41) 2.62 (0.83, 8.28)
Enthesitis Yes vs no 3.85 (1.33, 11.11)
SF-12-MCS Per unit increase 1.05 (1.02, 1.09) 1.05 (1.01, 1.08)
ASDAS Per unit increase 4.43 (2.83, 6.94)
Gender Female vs male 0.59 (0.29, 1.20)
Comorbidity count Per unit increase 0.64 (0.45, 0.92) 0.57 (0.37, 0.88) 0.60 (0.38, 0.95)
HADs anxiety Per unit increase 0.94 (0.88, 0.99)
Model fit ROC area under
curve (95% CI)
0.68 (0.61, 0.74) 0.71 (0.65, 0.77) 0.85 (0.80, 0.89) 0.81 (0.75, 0.86)
Sensitivity/Specificity
(%)
70.7/56.3 32.1/88.5 73.3/78.9 56.5/81.8
PPV/NPV 62.7/64.9 58.3/72.2 75.9/76.6 63.2/77.3
OR: odds ratio; ref: reference category; ASAS: assessment in ankylosing spondylitis; ASDAS: ankylosing spondylitis dis-
ease activity score; SF-12 MCS: short form 12 mental component score; SF-12 PCS: short form 12 physical component
score; HADS: hospital anxiety and depression scale; ROC: receiver operating characteristic; PPV: positive predictive value;
NPV: negative predictive value.
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present in trial populations. However, in contrast, it was
necessary to be flexible with respect to timing of
assessing outcome in this study as, although patients
were scheduled to be followed up at 3 and 6 months
after commencing their first anti-TNFa therapy, the
follow-up visit did not always happen at these times. A
follow-up of 3–4 months reflects UK clinical practice.
Indeed the National Institute of Health and Clinical
Excellence (NICE) recommends follow-up at 12 weeks
and that anti-TNF therapy should only be continued if
there is ‘clear evidence of response’ at this point [33].
With the knowledge that there may be some delays to
follow-up in the real world, we have chosen a longer
window for first follow-up to occur. The first visit in a
time window rather than at a specific time point has
been used. This option was chosen because patients
who attend a scheduled appointment may be more like-
ly to have clinical issues such as lack of efficacy or an
adverse event in comparison to those who choose not
to attend. However, if a patient had experienced a ser-
ious adverse event necessitating hospital admission this
would also result in failure to attend an appointment.
Thus, using a wider window of follow-up increased the
numbers whose outcome was assessed and potentially
decreased any ‘non-participation’ bias. In reality, the
distribution of follow-up time shows that half the partici-
pants were seen within a 5-week window. Secondly, the
patient-reported and clinical outcomes were not col-
lected at the same time. The follow-up study question-
naire was issued at the time follow-up was due and
therefore there was a difference between this and the
time the actual clinic visit took place. The median differ-
ence between the follow-up visit and follow-up ques-
tionnaire was 13 days (IQR –1, 34). Thirdly, at the time of
follow-up, some patients had stopped their anti-TNFa
therapy (e.g. due to an adverse event) and thus the in-
terpretation of our results is the prediction of outcome
amongst patients who commence their first anti-TNFa
rather than outcome while patients are still taking such
therapy. However, this is the most relevant question for
a clinician facing the decision on whether to commence
a patient on a specific therapy: ‘If I choose to prescribe
anti TNFa for this patient, how likely is it that they will/
will not have achieved a positive response in around 3–
4months?’.
There have only been few studies examining response
to biologic therapy in patients with axSpA. Molto et al.
hypothesized that patients with high enthesitis and/or
disease activity scores (BASDAI) may be less likely to
respond (on the basis that this could indicate co-morbid
fibromyalgia), but found that neither disease index influ-
enced likelihood of meeting ASAS40 or ASAS partial re-
mission criteria at 12 weeks [34]. Callhoff et al. reported
that the efficacy of anti-TNFa therapy was not related to
specific criteria satisfied (i.e. AS or non-radiographic
axial spondyloarthritis) [35]. The results of the current
study generally support these conclusions although the
presence of enthesitis and disease activity (as measured
by ASDAS) were the sole disease-related factors found
to relate to response in this study, and only for a single
outcome measure (reduction in ASDAS). An Italian multi-
centre retrospective study of 300 patients found that
the presence of enthesitis and psoriasis was associated
with lower likelihood of patients achieving at least partial
remission (which was defined as <20 mm in the four
domains of global assessment, spinal pain, function and
intensity/duration of morning stiffness). This study, how-
ever, did not collect any information on socio-economic
factors [36]. A report that appears to be from the same
study examines response by gender and found that
females were less likely to achieve partial remission than
males. It states that this was true also in a multivariable
model, but does not indicate what was included in the
model and there was no mention of any socio-economic
factors collected [37]. In the current study, for three out
of the four response criteria females were less likely to
respond, although none were statistically significant and
adding gender did not improve the fit of any of the mul-
tivariable models.
With respect to lifestyle factors predicting response, a
recent systematic review and meta-analysis has quanti-
fied the effect of obesity on response to anti TNFa ther-
apy across a range of immune-mediated inflammatory
diseases. Within this study, a sub-analysis of six studies
of spondyloarthropathies (including 966 patients of
whom 14% were obese) found increased odds of non-
response to therapy, but with considerable uncertainty
OR 3.4 95% CI (1.3, 8.5) [38]. In the current study,
higher levels of BMI were associated with non-response
(the OR per unit increase varied between 0.94 and 0.97
depending on the response criteria). However, only in
the multivariable model for ASAS20 did it significantly
improve model fit. The role of smoking in treatment re-
sponse is less clear. Current smoking has been related
to higher disease activity in patients with axSpA and AS
[39, 40], including observations of a pack-year/disease
activity dose-response [41]. Although studies of patients
with axSpA included in the Swiss Clinical Quality
Management Cohort as well as those in the DANBIO
Danish nationwide registry found that smokers had odds
of around 0.5 in meeting BASDAI50 response criteria (in
comparison to non-smokers) [42, 43] data from the
BSRBR-AS did not find smoking to be a predictor of re-
sponse to TNFa inhibitors and suggested that previous
observations of an association may be explained by
methodological factors [44].
What has this study added to our existing knowledge?
It has demonstrated that, generally, disease specific fac-
tors do not predict response to first anti-TNFa therapy.
The factors that predict response across different crite-
ria are not modifiable at least by the rheumatologist in
the clinic. Factors such as level of deprivation, level
of education and employment status are, however,
identifying persons who may need additional manage-
ment in order to derive the benefit that other patients
receive from anti-TNFa therapy. This may include
support for self-management including education, or
non-pharmacological therapy (such as physical therapy
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or input from an occupational therapist), and this could
usefully be the focus for testing in future studies. Poor
mental health is also a marker of lower likelihood of re-
sponse across criteria and patients with such markers
of poor response may need specific assessment and
behavioural therapy or psychological support in order
for to derive benefit from pharmacological therapy.
Retiring or not being in employment due to ill-health is a
strong and consistent predictor of non-response across
the models; future work should identify the reasons (dis-
ease-specific or contextual) why this is the case.
In conclusion, the statistical models in this study iden-
tify patients with a high likelihood (70–80%) of not
responding to their first biologic therapy for axSpA—
some (such as mental health) are modifiable, whereas
others (such as social and economic factors) do not
lend themselves to modification in the clinic—but iden-
tify patients who otherwise are unlikely to benefit from
biologic therapy alone. Priority should be focused on
how we ensure that these patients receive the benefits
that many patients derive from such therapies. It also
emphasizes that examination of predictors of non-
response to pharmacologic therapy in inflammatory arth-
ritis must consider the importance of socio-economic
factors.
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